These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 511368)
1. 25-hydroxycholecalciferol in the treatment of renal osteodystrophy in haemodialysed patients. Coen G; Taccone-Gallucci M; Bonucci E; Bianchini G; Gallucci G; Lucentini G; Matteucci MC; Picca S; Casciani CU Int J Artif Organs; 1979 Nov; 2(6):278-81. PubMed ID: 511368 [TBL] [Abstract][Full Text] [Related]
2. Whole-body in-vivo neutron activation analysis in assessing treatment of renal osteodystrophy with 1-alpha-hydroxycholecalciferol. Naik RB; Gosling P; Price CP; Robinson BH; Dabek JT; Heath DA; James HM; Kanis JA; Smith R Br Med J; 1976 Jul; 2(6027):79-83. PubMed ID: 1276820 [TBL] [Abstract][Full Text] [Related]
3. 1-alpha-hydroxycholecalciferol for renal osteodystrophy. Brownjohn AM; Goodwin FJ; Hately W; Marsh FP; O'Riordan JL; Papapoulos SE Br Med J; 1977 Sep; 2(6089):721-3. PubMed ID: 912269 [TBL] [Abstract][Full Text] [Related]
4. Histopathology of renal osteodystrophy with particular reference to the effects of 1alpha-hydroxyvitamin D3 in patients treated by long-term haemodialysis. Ellis HA; Pierides AM; Feest TG; Ward MK; Kerr DN Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():31s-38s. PubMed ID: 606422 [TBL] [Abstract][Full Text] [Related]
5. Comparison of 1,25(OH)2D3 and 24,25(OH)2D3 in the long-term treatment of renal osteodystrophy. Muirhead N; Catto GR; Edward N; Fraser RA; O'Riordan JL; Papapoulos SE; Adami S Proc Eur Dial Transplant Assoc; 1980; 17():543-7. PubMed ID: 6972529 [TBL] [Abstract][Full Text] [Related]
6. Use of 1,25(OH)2-vitamin D3 to separate 'types' on renal osteodystrophy. Coburn JW; Brickman AS; Sherrard DJ; Singer FR; Wong EG; Baylink DJ; Norman AW Proc Eur Dial Transplant Assoc; 1977; 14():442-50. PubMed ID: 600961 [TBL] [Abstract][Full Text] [Related]
7. Long-term effects of small doses of 1,25-dihydroxycholecalciferol in renal osteodystrophy. Ahmed KY; Varghese Z; Wills MR; Meinhard EA; Moorhead JF Lancet; 1978 Mar; 1(8065):629-32. PubMed ID: 76168 [TBL] [Abstract][Full Text] [Related]
8. [Renal osteodystrophy in two children : a comparison of the effects of 1 alpha-hydroxycholecalciferol (author's transl)]. Chantraine JM; Davin JC; Lambrechts L; Heynen G Ann Endocrinol (Paris); 1979; 40(2):161-2. PubMed ID: 475307 [TBL] [Abstract][Full Text] [Related]
9. Treatment of renal osteodystrophy with 1,25-dihydroxycholecalciferol. Velentzas C; Oreopoulos DG; Pierratos A; Meema HE; Rabinovich S; Meindok H; Husdan H; Murray TM; Ogilvie R; Katirtzoglou A Can Med Assoc J; 1981 Mar; 124(5):577-83. PubMed ID: 6894103 [TBL] [Abstract][Full Text] [Related]
10. 1 alpha hydroxycholecalciferol and 25 hydroxycholecalciferol in renal bone disease. Fournier AE; Bordier PJ; Gueris J; Chanard J; Marie P; Ferriere C; Osario M; Bedrossian J; de Luca HF Proc Eur Dial Transplant Assoc; 1976; 12():227-36. PubMed ID: 935115 [TBL] [Abstract][Full Text] [Related]
11. 1alpha-hydroxycholecalciferol: a promising therapeutic approach for renal osteodystrophy. Gotloib L; Mines M; Mazur Y; Sklan D; Garmizo AL; Jancu J; Israeli M; Malul M Isr J Med Sci; 1978 Jul; 14(7):731-5. PubMed ID: 681163 [TBL] [Abstract][Full Text] [Related]
13. Comparison of 1 alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in the treatment of renal osteodystrophy: greater effect of 25-hydroxycholecalciferol on bone mineralization. Fournier A; Bordier P; Gueris J; Sebert JL; Marie P; Ferrière C; Bedrossian J; DeLuca HF Kidney Int; 1979 Feb; 15(2):196-204. PubMed ID: 513484 [No Abstract] [Full Text] [Related]
14. Long-term treatment of postmenopausal osteoporosis with active vitamin D3, 1-alpha-hydroxycholecalciferol (1 alpha-OHD3) and 1, 24 Dihydroxycholecalciferol (1, 24(OH)2D3). Shiraki M; Orimo H; Ito H; Akiguchi I; Nakao J; Takahashi R; Ishizuka S Endocrinol Jpn; 1985 Apr; 32(2):305-15. PubMed ID: 2995014 [TBL] [Abstract][Full Text] [Related]
15. The investigation and treatment of renal osteodystrophy. Catto GR; MacLeod M; Pelc B; Kodicek E Proc Eur Dial Transplant Assoc; 1975; 11():473-80. PubMed ID: 1197272 [TBL] [Abstract][Full Text] [Related]
16. Effects of 25-hydroxycholecalciferol on bone lesions of children with terminal renal failure. Witmer G; Margolis A; Fontaine O; Fritsch J; Lenoir G; Broyer M; Balsan S Kidney Int; 1976 Nov; 10(5):395-408. PubMed ID: 794558 [TBL] [Abstract][Full Text] [Related]
17. 1,25-dihydroxycholecalciferol in renal osteodystrophy. Epiphysiolysis--anticonvulsant therapy. Pierides AM; Ellis HA; Dellagrammatikas H; Scott JE; Norman AW Arch Dis Child; 1977 Jun; 52(6):464-72. PubMed ID: 879832 [TBL] [Abstract][Full Text] [Related]
18. Treatment of renal osteodystrophy with 1alpha-hydroxycholecalciferol (1alpha-OH-D3) in conjunction with a high dialysate calcium. Winney RJ; Bone JM; Anderson TJ; Robson JS Calcif Tissue Res; 1977 May; 22 Suppl():94-100. PubMed ID: 912593 [No Abstract] [Full Text] [Related]
19. [Renal osteodystrophy: the importance of 1-alpha-OH-D3]. Berland Y; Olmer M; Grandvuillemin M; Lachaize AM Sem Hop; 1981 Mar 8-15; 57(9-10):445-9. PubMed ID: 6261385 [TBL] [Abstract][Full Text] [Related]
20. Calcitriol in dialysis patients. Maxwell DR; Benjamin DM; Donahay SL; Allen MK; Hamburger RJ; Luft FC Clin Pharmacol Ther; 1978 May; 23(5):515-9. PubMed ID: 205382 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]